ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Chronic Active Antibody Mediated Rejection (cABMR): Treatment, Outcomes and Predictors of Graft Loss in a Large Case Series

R. Redfield,1 T. Ellis,1 W. Zhong,1 T. Zens,1 M. Rizzari,1 J. Scalea,1 L. Jacobson,1 D. Mandelbrot,1 S. Parajuli,1 B. Muth,1 M. Mohamed,1 S. Panzer,1 B. Astor,1 M. Samaniego,2 D. Kaufman,1 A. Djamali.1

1University of Wisconsin, Madison, WI
2University of Michigan, Ann Arbor, MI.

Meeting: 2015 American Transplant Congress

Abstract number: A94

Keywords: Alloantibodies, Graft survival, Rejection

Session Information

Session Name: Poster Session A: Kidney Antibody Mediated Rejection

Session Type: Poster Session

Date: Saturday, May 2, 2015

Session Time: 5:30pm-7:30pm

 Presentation Time: 5:30pm-7:30pm

Location: Exhibit Hall E

Background: CABMR is a barrier to long-term kidney allograft survival. There is little information on the treatment and outcomes of kidney transplant recipients with cABMR.

Methods: A single institution study of 124 patients diagnosed with cABMR of the kidney between 2006 and 2012. All biopsies were based on clinical indication and met Banff 2013 criteria for cABMR.

Results: The diagnosis of cABMR was made at a mean of 5.6 ± 3.8 years post transplant. Patients were followed for 10±4 years (range 2.7 to 20.3) post-transplant. Mean DSA at time of diagnosis was 12,000 ±12,700 MFI. The majority (53.2%) of patients had class II antibodies, 32.2% had both class I and II antibodies and a minority (14.5%) had class I DSA only. At the time of diagnosis, mean C4d and cg scores were 2.6±0.7 and 2.2±0.8 respectively. Mean chronicity score (ci+ct+cg+cv) was 6.2±2 (Median 6) and mean MVI score (ptc+g) was 2.1±1.4 (Median 2).

There were 31 (25%) patient deaths and 94 (76%) graft losses, which occurred at a mean of 1.5±1.4 years after cABMR diagnosis. Patients were treated with steroid bolus (93%), IVIG (87%), rituximab (30%), plasma exchange (PLEX, 13%) and Thymoglobulin (10%). Treatment of any kind was associated with superior graft survival at 3 years from diagnosis of cABMR (34% vs 10%, p=0.05).

In unadjusted analyses, cv>1 (HR 1.6, CI 1.0 to 2.6, p=0.04), DSA > 7,000 MFI (HR 1.7, CI 1.1 to 2.5, p=0.01) were independently associated with graft loss. Rituximab (HR 0.52, CI 0.33 to 0.83, p=0.01) and Thymoglobulin treatment (HR 0.42, CI 0.18 to 0.98, p=0.04) were independently associated with graft protection. In multivariate analyses, only MFI > 7,000 MFI (HR 1.6, CI 1.0 to 2.4, p=0.04) and rituximab (HR 0.54, CI 0.34 to 0.88, p=0.01) were retained as significant.

Conclusion: cABMR is associated with poor graft survival. In this large case series of kidney transplant recipients with cABMR, DSA intensity was identified as a predictor of graft loss and rituximab therapy as a predictor of graft survival. Rituximab may have beneficial effects in preventing graft demise. Randomized clinical trials are needed to confirm these findings and define the best strategy to treat cABMR.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Redfield R, Ellis T, Zhong W, Zens T, Rizzari M, Scalea J, Jacobson L, Mandelbrot D, Parajuli S, Muth B, Mohamed M, Panzer S, Astor B, Samaniego M, Kaufman D, Djamali A. Chronic Active Antibody Mediated Rejection (cABMR): Treatment, Outcomes and Predictors of Graft Loss in a Large Case Series [abstract]. Am J Transplant. 2015; 15 (suppl 3). https://atcmeetingabstracts.com/abstract/chronic-active-antibody-mediated-rejection-cabmr-treatment-outcomes-and-predictors-of-graft-loss-in-a-large-case-series/. Accessed May 8, 2025.

« Back to 2015 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences